Evidence map›Paper›PMID 38656269›Full record

ArticleThe Journal of international medical research2024

Successful guselkumab treatment of a refractory psoriasis patient with Graves' disease: a case report.

Xinyi Shao, Kun Huang, Aijun Chen, Chuan Liu, Jianxia Xiong, Yun Pan, Xiaoli Chen, Ping Wang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of international medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xinyi ShaoDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID 0000-0001-7780-139X
Kun HuangDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Aijun ChenDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Chuan LiuDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Jianxia XiongDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yun PanDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xiaoli ChenDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID 0000-0003-2456-9173
Ping WangDepartment of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID 0000-0001-6181-3556
The Affiliated Yongchuan Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis is a chronic inflammatory skin disease. It is associated with many autoimmune diseases such as rheumatoid arthritis, Crohn's disease and thyroid diseases. Graves' disease (GD) is a common organ-specific autoimmune disease characterized by diffuse goitre and thyrotoxicosis. Management of psoriasis patients with GD is challenging. This current report presents the case of a 34-year-old female patient with refractory psoriasis with GD who was hospitalized for drug eruption and then experienced new-onset erythema and scaling following treatment with adalimumab and secukinumab. Despite the sequential move to phototherapy, tofacitinib and ustekinumab, the erythema and scaling continued unabated and exacerbated. Finally, switching to guselkumab resulted in the psoriasis lesions significantly improving. These findings suggest that guselkumab might be an effective treatment option for refractory psoriasis combined with GD.

Indexed as

Antibodies, Monoclonal, HumanizedGraves DiseasePsoriasisAdultFemaleHumansTreatment OutcomeAntibodies, Monoclonal, Humanizedguselkumabbiological agentGraves’ diseaseGuselkumabpsoriasisrefractory

Identifiers

PMID38656269
PMCPMC11044775
OpenAlexW4395072478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.